Recursion Pharmaceuticals RXRX reported a loss of 22 cents per share in the third quarter of 2026, narrower than the Zacks ...

Recursion Q3 2026 earnings: clinical wins for REC-4881 and REC-1245, Sanofi progress, and cash runway to 2029.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent intraday, after Sanofi finally pulled the trigger on the development of ...

Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...

Recursion Pharmaceuticals (NASDAQ:RXRX) reported updated clinical data for its investigational treatment for familial ...

The latest update is out from Recursion Pharmaceuticals ( (RXRX) ).

Recursion Pharmaceuticals RXRX, a TechBio company, is expected to beat expectations when it reports third-quarter 2026 ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...

Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and ...